<DOC>
	<DOCNO>NCT00018031</DOCNO>
	<brief_summary>This study evaluate safety effectiveness combination therapy peginterferon alfa-2b ribavirin treat hepatitis C virus ( HCV ) infection HIV-infected patient . In study patient hepatitis C alone , interferon alfa-2b plus ribavirin treatment eradicate HCV almost half patient . Peginterferon alfa-2b compound result attach polyethylene glycol molecule interferon alfa-2b . This compound stay blood longer unmodified interferon alfa-2b , cause high blood concentration thus maintain activity hepatitis C virus . HIV-infected patient 21 year age old chronic hepatitis C infection viral load great 2000 copies/mL may eligible 2 1/2-year study . Candidates screen blood urine test possibly liver biopsy , recent one available . The liver biopsy do determine severity liver disease . For test , patient admit NIH Clinical Center 1 2 day . A sedative injected arm vein , skin area biopsy site numb local anesthetic , needle insert rapidly liver obtain small tissue sample . The patient remain hospital overnight monitoring . A chest X-ray , electrocardiogram ( EKG ) liver ultrasound also do . Within 4 week screen test , candidate appear eligible study physical examination , medical history repeat blood test . Women become pregnant serial pregnancy test throughout study . Patients meet study criterion decide participate begin treatment weekly injection skin peginterferon alfa-2b take ribavirin pill twice day mouth . In addition , patient continue take medication prescribe doctor . Clinic visit schedule follow : - Days 1 , 3 , 5 , 7 , 10 21 - Blood drawn safety test measure blood level HIV HCV . - Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 , 44 , 52 , 56 64 - Blood urine test do determine side effect treatment effect HCV infection . - Week 48 end treatment - Treatment stop 48 week . At time , early complete 48 week , patient return clinic routine test .</brief_summary>
	<brief_title>Peginterferon Alpha-2b And Ribavirin Treat Hepatitis C HIV-Infected Patients</brief_title>
	<detailed_description>Hepatitis C infection occur one-third HIV-infected individual . Liver disease become clinically significant among patient coinfected HIV HCV . Several study show coinfected individual develop earlier severe liver disease . Interferon ribavirin become therapy choice among people non-genotype 1a . This pilot study address relationship clinical response combination therapy virologic immunologic parameter . The study also address safety efficacy peginterferon alfa-2b among HIV- infected individual . The predictive ability baseline HCV viral load , rate decline HCV viral load , HIV viral load CD4 count clinical response chronic hepatitis peginterferon ribavirin also study . Approximately sixty patient infect HIV HCV also evidence fibrosis receive peginterferon alfa-2b ribavirin 48 week . In order enroll sixty patient study , screen total 180 patient . During 72 week study patient monitor HCV viral load , HIV viral load CD4 count . Viral kinetics also monitor closely slope second , slow phase decline HCV viral load , correspond rate infect cell death presumably may lead sustain hepatitis C virologic response . The result study enable u good delineate possible predictor sustain response peginterferon ribavirin . The safety tolerability combination therapy peginterferon ribavirin among HIV-infected individual antiretroviral therapy define standard therapy chronic hepatitis C HIV-infected individual .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year . Documentation HIV1 infection license ELISA test confirm Western Blot . Documentation Hepatitis C infection demonstration positive test hepatitis C antibody . HCV RNA level great 2000 IU/ml bDNA . Infected HCV genotype 1 . Histopathologic feature consistent chronic hepatitis C liver biopsy time enrollment . Patients CD4 great 300 cells/mm ( 3 ) . Ability sign inform consent willingness comply study requirement clinic policy . Serum creatinine le 1.5 mg/dL . Serum phosphorus great equal 2.2 mg/dL ( normal range NIH 2.34.3 mg/dL ) . Neutrophil count great equal 1000 cells/mm ( 3 ) . Platelets great equal 75,000/mm ( 3 ) . Hemoglobin great equal 8.0 mg/dL . ALT less 7 time NIH upper limit normal . Serum lipase less 1.5 time NIH upper limit normal . Not pregnant breastfeeding . Pregnancy test must negative within two week prior dose study medication . If capable pregnancy : use effective contraception study : effective contraception method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap sponge , use hormonal contraception antiHIV regimen alter metabolism hormonal contraception . This advised basis use ribavirin , may potential teratogenic effect pregnant woman . Need primary doctor outside OP8 take care patient HIV infection liver disease . Willing designate person durable power attorney NIH form medical research medical care purpose NIH Clinical Center . Ability learn safely inject medication subcutaneously . EXCLUSION CRITERIA : PTINR ( absence anticardiolipin antibody ) prolong great 2 second . Organ transplant recipient . Elevated alphafetoprotein level ( great 100 ng/mL ) . Coexisting neoplastic disease require cytotoxic therapy . Child Pugh 's class B . Severe cardiac pulmonary decompensation . Severe liver decompensation advance cirrhosis patient . Severe psychiatric disorder would interfere adherence protocol requirement . Preexisting autoimmune disorder include inflammatory bowel disease , psoriasis , optic neuritis . Preexisting uncontrolled seizure disorder . Severe retinopathy . Hemoglobinopathy Direct bilirubin equal 2 time ULN . No patient use long term systemic corticosteroid , immunosuppressive , cytotoxic agent within 60 day enrollment trial . Chronic viral hepatitis etiology hepatitis C. Active systemic infection hepatitis C HIV . Liver disease cause reason hepatitis C like HBV , HDV , Wilson 's hemochromatosis , autoimmune hepatitis ( ANA great 160 ) except history drugassociated hepatitis discontinuation causative agent . Hepatic mass suggestive hepatocellular carcinoma . Current alcohol substance abuse potentially could interfere patient compliance . Significant heart failure . Evidence esophageal varix . Any systemic illness make unlikely subject able return NIH require study visit . Evidence gastrointestinal malabsorption chronic nausea vomit . Male partner pregnant woman . Currently take didanosine ( ddl VidexEC Videx ) part antiretroviral regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Liver Disease</keyword>
	<keyword>Virologic Response</keyword>
	<keyword>Immune Mechanisms</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Eradication</keyword>
	<keyword>HIV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>